These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24582495)

  • 21. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B; Sharma A; Woo S
    PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.
    Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W
    Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.
    Wang LJ; He CC; Sui X; Cai MJ; Zhou CY; Ma JL; Wu L; Wang H; Han SX; Zhu Q
    Oncotarget; 2015 Mar; 6(8):5932-46. PubMed ID: 25803229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
    Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
    Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-101 inhibits the migration and invasion of intrahepatic cholangiocarcinoma cells via direct suppression of vascular endothelial growth factor-C.
    Deng G; Teng Y; Huang F; Nie W; Zhu L; Huang W; Xu H
    Mol Med Rep; 2015 Nov; 12(5):7079-85. PubMed ID: 26299768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
    Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway.
    Chen Z; He B; Zhao J; Li J; Zhu Y; Li L; Bao W; Zheng J; Yu H; Chen G
    Phytomedicine; 2022 Sep; 104():154323. PubMed ID: 35858516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced RASGEF1A expression is involved in the growth and migration of intrahepatic cholangiocarcinoma.
    Ura K; Obama K; Satoh S; Sakai Y; Nakamura Y; Furukawa Y
    Clin Cancer Res; 2006 Nov; 12(22):6611-6. PubMed ID: 17121879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma.
    El Khatib M; Kalnytska A; Palagani V; Kossatz U; Manns MP; Malek NP; Wilkens L; Plentz RR
    Hepatology; 2013 Mar; 57(3):1035-45. PubMed ID: 23172661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.
    Acker G; Zollfrank J; Jelgersma C; Nieminen-Kelhä M; Kremenetskaia I; Mueller S; Ghori A; Vajkoczy P; Brandenburg S
    Eur J Cancer; 2020 Feb; 126():106-115. PubMed ID: 31927212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K/AKT signaling upon CD97 activation.
    Meng ZW; Zhang L; Cai XR; Wang X; She FF; Chen YL
    Sci Rep; 2023 Oct; 13(1):18711. PubMed ID: 37907543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma.
    Park BK; Paik YH; Park JY; Park KH; Bang S; Park SW; Chung JB; Park YN; Song SY
    Am J Clin Oncol; 2006 Apr; 29(2):138-42. PubMed ID: 16601431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma.
    Zhao Z; Ma J; Wu K; Chen L; Yu J; Hu W; Zhang K
    Clin Transl Oncol; 2016 Sep; 18(9):878-83. PubMed ID: 26563145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma.
    Li S; Chai Y; Ding Y; Yuan T; Wu C; Huang C
    Oncol Rep; 2019 Aug; 42(2):657-669. PubMed ID: 31173252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma.
    Min JK; Kim JM; Li S; Lee JW; Yoon H; Ryu CJ; Jeon SH; Lee JH; Kim JY; Yoon HK; Lee YK; Kim BH; Son YS; Choi HS; Lim NK; Kim DG; Hong HJ
    Clin Cancer Res; 2010 Jul; 16(14):3571-80. PubMed ID: 20501614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma.
    Zhang MX; Gan W; Jing CY; Zheng SS; Yi Y; Zhang J; Xu X; Lin JJ; Zhang BH; Qiu SJ
    Mol Carcinog; 2019 Jan; 58(1):19-30. PubMed ID: 30182496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of the selective and non-peptide CXCR2 receptor antagonist SB225002 on acute and long-lasting models of nociception in mice.
    Manjavachi MN; Quintão NL; Campos MM; Deschamps IK; Yunes RA; Nunes RJ; Leal PC; Calixto JB
    Eur J Pain; 2010 Jan; 14(1):23-31. PubMed ID: 19264522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.
    Yang B; Tong R; Liu H; Wu J; Chen D; Xue Z; Ding C; Zhou L; Xie H; Wu J; Zheng S
    Int J Oncol; 2018 Apr; 52(4):1235-1245. PubMed ID: 29532867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
    Peng H; Zhang Q; Li J; Zhang N; Hua Y; Xu L; Deng Y; Lai J; Peng Z; Peng B; Chen M; Peng S; Kuang M
    Oncotarget; 2016 Mar; 7(13):17220-9. PubMed ID: 26967384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.